201 related articles for article (PubMed ID: 38019516)
41. Cost-Effectiveness Analysis of Prostate-Specific Antigen Screening Among Chinese Men.
Zhao G; Shao Y; Zhang N; Wang J; Yuan L; Sun X; Shi L
Value Health Reg Issues; 2020 May; 21():272-279. PubMed ID: 32402819
[TBL] [Abstract][Full Text] [Related]
42. Cost-Effectiveness of Open Versus Endoscopic Carpal Tunnel Release.
Barnes JI; Paci G; Zhuang T; Baker LC; Asch SM; Kamal RN
J Bone Joint Surg Am; 2021 Feb; 103(4):343-355. PubMed ID: 33591684
[TBL] [Abstract][Full Text] [Related]
43. Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations.
Earnshaw SR; McDade CL; Black LK; Bell CF; Kattan MW
Pharmacoeconomics; 2010; 28(6):489-505. PubMed ID: 20196623
[TBL] [Abstract][Full Text] [Related]
44. Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment.
Govers TM; Caba L; Resnick MJ
J Urol; 2018 Dec; 200(6):1221-1226. PubMed ID: 30012363
[TBL] [Abstract][Full Text] [Related]
45. Cost-effectiveness of culture-guided antimicrobial prophylaxis for the prevention of infections after prostate biopsy.
Li CK; Tong BCY; You JHS
Int J Infect Dis; 2016 Feb; 43():7-12. PubMed ID: 26686941
[TBL] [Abstract][Full Text] [Related]
46. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
47. Cost Utility of Lifelong Immunoglobulin Replacement Therapy vs Hematopoietic Stem Cell Transplant to Treat Agammaglobulinemia.
Sun D; Heimall JR; Greenhawt MJ; Bunin NJ; Shaker MS; Romberg N
JAMA Pediatr; 2022 Feb; 176(2):176-184. PubMed ID: 34779842
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness analysis of short biparametric magnetic resonance imaging protocol in men at risk of prostate cancer.
Faccioli N; Santi E; Foti G; Curti P; D'Onofrio M
Arch Ital Urol Androl; 2022 Jun; 94(2):160-165. PubMed ID: 35775339
[TBL] [Abstract][Full Text] [Related]
49. Cost-Effectiveness of Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study.
Hao S; Karlsson A; Heintz E; Elfström KM; Nordström T; Clements M
Value Health; 2021 Dec; 24(12):1763-1772. PubMed ID: 34838274
[TBL] [Abstract][Full Text] [Related]
50. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
van der Leest M; Cornel E; Israël B; Hendriks R; Padhani AR; Hoogenboom M; Zamecnik P; Bakker D; Setiasti AY; Veltman J; van den Hout H; van der Lelij H; van Oort I; Klaver S; Debruyne F; Sedelaar M; Hannink G; Rovers M; Hulsbergen-van de Kaa C; Barentsz JO
Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981
[TBL] [Abstract][Full Text] [Related]
51. A Cost-Utility Analysis of Prostate Cancer Screening in Australia.
Keller A; Gericke C; Whitty JA; Yaxley J; Kua B; Coughlin G; Gianduzzo T
Appl Health Econ Health Policy; 2017 Feb; 15(1):95-111. PubMed ID: 27757918
[TBL] [Abstract][Full Text] [Related]
52. Real-world use of MRI for risk stratification prior to prostate biopsy.
Siddiqui MR; Ansbro B; Shah PV; Aguiar JA; Li EV; Rich JM; Mahenthiran AK; Moataz SAS; Keeter MK; Mai Q; Mi X; Schaeffer EM; Ross AE
Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):353-359. PubMed ID: 35551235
[TBL] [Abstract][Full Text] [Related]
53. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility.
van der Leest M; Israël B; Cornel EB; Zámecnik P; Schoots IG; van der Lelij H; Padhani AR; Rovers M; van Oort I; Sedelaar M; Hulsbergen-van de Kaa C; Hannink G; Veltman J; Barentsz J
Eur Urol; 2019 Nov; 76(5):574-581. PubMed ID: 31167748
[TBL] [Abstract][Full Text] [Related]
54. Cost-Effectiveness Analysis of Stockholm 3 Testing Compared to PSA as the Primary Blood Test in the Prostate Cancer Diagnostic Pathway: A Decision Tree Approach.
Risør BW; Tayyari Dehbarez N; Fredsøe J; Sørensen KD; Pedersen BG
Appl Health Econ Health Policy; 2022 Nov; 20(6):867-880. PubMed ID: 35934771
[TBL] [Abstract][Full Text] [Related]
55. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.
Jayadevan R; Felker ER; Kwan L; Barsa DE; Zhang H; Sisk AE; Delfin M; Marks LS
JAMA Netw Open; 2019 Sep; 2(9):e1911019. PubMed ID: 31509206
[TBL] [Abstract][Full Text] [Related]
56. Cost-Effectiveness of Multiparametric Magnetic Resonance Imaging and Targeted Biopsy Versus Systematic Transrectal Ultrasound-Guided Biopsy for Prostate Cancer Diagnosis: A Systematic Review.
Rezapour A; Alipour V; Moradi N; Arabloo J
Value Health Reg Issues; 2022 Jul; 30():31-38. PubMed ID: 35042021
[TBL] [Abstract][Full Text] [Related]
57. Cost-Effectiveness Analysis and Microsimulation of Serial Multiparametric Magnetic Resonance Imaging in Active Surveillance of Localized Prostate Cancer.
Magnani CJ; Hernandez-Boussard T; Baker LC; Goldhaber-Fiebert JD; Brooks JD
J Urol; 2022 Jul; 208(1):80-89. PubMed ID: 35212570
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness of Intensive vs Standard Blood Pressure Control Among Older Patients With Hypertension.
Liao CT; Toh HS; Sun L; Yang CT; Hu A; Wei D; Melgarejo J; Zhang ZY
JAMA Netw Open; 2023 Feb; 6(2):e230708. PubMed ID: 36848091
[TBL] [Abstract][Full Text] [Related]
59. The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study.
Getaneh AM; Heijnsdijk EAM; de Koning HJ
Sci Rep; 2021 Jan; 11(1):1801. PubMed ID: 33469144
[TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
Chen JV; Klein TM; Nesheim J; Mudd PN
J Med Econ; 2022; 25(1):1092-1100. PubMed ID: 35993729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
